Hereditary Hypophosphatemia: Diagnostic Challenges and Potential New Approaches- Enduring

This course was a live CME-certified Ancillary Symposium presented at Endocrine Society Annual Meeting (ENDO) 2018, held in Chicago, IL. This educational activity is supported by an independent medical educational grant from Ultragenyx Pharmaceuticals. Presented through a collaboration between the Endocrine Society and Medscape Education. 


Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.

Learning Objectives

Upon completion of this activity, learners will have:

Increased knowledge regarding

  • Diagnosis of hypophosphatemia related to chronic renal phosphate wasting

  • Current treatment strategies for hereditary hypophosphatemia

  • Emerging approaches that target the underlying pathophysiologic changes leading to phosphorus imbalance

Greater competence related to

  • Overcoming diagnostic challenges associated with hypophosphatemic disorders

  • Developing treatment strategies for patients with hypophosphatemia

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation
Course opens: 
Course expires: 

Program Chair
Leanne Ward, MD, FRCPC
Associate Professor; Director, Bone Health Program
University of Ottawa,
Ottawa, Ontario, Canada

Karl L. Insogna, MD
Ensign Professor of Medicine, Department of Internal Medicine/Endocrinology
Director, Yale Bone Center
Associate Director, Yale Center for X-Linked Hypophosphatemia
New Haven, Connecticut, United States

Farzana Perwad, MD
Associate Professor; Chief, Division of Pediatric Nephrology, Department of Pediatrics 
University of California
San Francisco, California, United States

Peter J. Tebben, MD
Assistant Professor of Medicine and Pediatrics;
Director Pediatric Bone Clinic, Mayo Clinic
Rochester, Minnesota, United States


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Leanne Ward, MD, FRCPC: Advisory Board, Ultragenyx, Amgen Inc, Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc.; Consultant, Ultragenyx, Alexion Pharmaceuticals, Inc.; Research Investigator, Amgen Inc, Novartis Pharmaceuticals, Ultragenyx; Speaker, Alexion Pharmaceuticals, Inc.
Karl L. Insogna, MD: Consultant, Ultragenyx; Research Support, Ultragenyx
Farzana Perwad, MD: Consultant, Ultragenyx
Peter J. Tebben, MD: Grant, Ultragenyx, Alexion

The following SPC members who planned and reviewed content for this activity reported relevant financial relationships:
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire

The following SPC members reported relevant financial relationships:
Zahid Ahmad, MD:Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD:Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD:Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Amy Rothberg, MD, Susmeeta Sharma, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Click "Start" to complete meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with


The Endocrine Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™ and 2.5 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions about content or obtaining CME credit, please contact the Endocrine Society at


Review your ABIM Diplomate ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM) or American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABP or ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation